Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Current Leases (2019 - 2025)

Historic Current Leases for Guided Therapeutics (GTHP) over the last 7 years, with Q3 2025 value amounting to $76000.0.

  • Guided Therapeutics' Current Leases fell 2549.02% to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $76000.0, marking a year-over-year decrease of 2549.02%. This contributed to the annual value of $106000.0 for FY2024, which is 1648.35% up from last year.
  • Guided Therapeutics' Current Leases amounted to $76000.0 in Q3 2025, which was down 2549.02% from $104000.0 recorded in Q2 2025.
  • Guided Therapeutics' Current Leases' 5-year high stood at $110000.0 during Q1 2025, with a 5-year trough of $42000.0 in Q1 2021.
  • For the 5-year period, Guided Therapeutics' Current Leases averaged around $82684.2, with its median value being $82000.0 (2023).
  • Its Current Leases has fluctuated over the past 5 years, first plummeted by 5757.58% in 2021, then soared by 6666.67% in 2022.
  • Guided Therapeutics' Current Leases (Quarter) stood at $67000.0 in 2021, then grew by 17.91% to $79000.0 in 2022, then rose by 15.19% to $91000.0 in 2023, then rose by 16.48% to $106000.0 in 2024, then decreased by 28.3% to $76000.0 in 2025.
  • Its last three reported values are $76000.0 in Q3 2025, $104000.0 for Q2 2025, and $110000.0 during Q1 2025.